Atlas Trials

Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.

Clinical trial NCT00159471 · TERMINATED

Trial details

NCT number
NCT00159471
Sponsor
University of Southern California
Status
TERMINATED
Phase
Not Applicable
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2005-02-01
Primary completion
2006-06-01
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.